China Pharma Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 14, 2017 and accepted by EDGAR at Nov 14, 2017, 15:57 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-07-01 to 2017-09-30 | $3.2m | us-gaap:Revenues |
| Revenue | 9 months2017-01-01 to 2017-09-30 | $9.4m | us-gaap:Revenues |
| Cost of revenue | 3 months2017-07-01 to 2017-09-30 | $2.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2017-01-01 to 2017-09-30 | $7.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2017-07-01 to 2017-09-30 | $421.5k | us-gaap:GrossProfit |
| Gross profit | 9 months2017-01-01 to 2017-09-30 | $1.8m | us-gaap:GrossProfit |
| Research and development | 3 months2017-07-01 to 2017-09-30 | $27.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $75.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$2.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | −$5.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-07-01 to 2017-09-30 | $130.8k | us-gaap:InterestExpense |
| Interest expense | 9 months2017-01-01 to 2017-09-30 | $412.0k | us-gaap:InterestExpense |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $31.2k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | $92.1k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$2.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | −$5.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | −$0.05 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | −$0.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $67.3k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-09-30 | $1.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $15.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $75.0m | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $10.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $18.0m | us-gaap:Liabilities |
| Long-term debt | At period end2017-09-30 | $9.2m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2017-09-30 | $57.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-17-012067. Last ingested by Listed: Nov 11, 2026, 00:23 ET. Listed shows no prices and gives no investment advice.